215 related articles for article (PubMed ID: 37744243)
1. Development and validation of a personalized classifier to predict the prognosis and response to immunotherapy in glioma based on glycolysis and the tumor microenvironment.
Fan P; Xia J; Zhou M; Zhuo C; He H
PeerJ; 2023; 11():e16066. PubMed ID: 37744243
[TBL] [Abstract][Full Text] [Related]
2. The combined signatures of telomere and immune cell landscape provide a prognostic and therapeutic biomarker in glioma.
Han X; Yan Z; Fan K; Guan X; Hu B; Li X; Ou Y; Cui B; An L; Zhang Y; Gong J
Front Immunol; 2023; 14():1220100. PubMed ID: 37662954
[TBL] [Abstract][Full Text] [Related]
3. Development of personalized classifier based on metastasis and the immune microenvironment to predict the prognosis of osteosarcoma patients.
Zhang Z; Yuan J; Wang Y; Zhang Y; Guan Z; Su X; Wang Y
Ann Transl Med; 2022 Dec; 10(24):1346. PubMed ID: 36660665
[TBL] [Abstract][Full Text] [Related]
4. Prediction of survival and immunotherapy response by the combined classifier of G protein-coupled receptors and tumor microenvironment in melanoma.
Shen K; Wang Q; Wang L; Yang Y; Ren M; Li Y; Gao Z; Zheng S; Ding Y; Ji J; Wei C; Zhang T; Zhu Y; Feng J; Qin F; Yang Y; Wei C; Gu J
Eur J Med Res; 2023 Sep; 28(1):352. PubMed ID: 37716991
[TBL] [Abstract][Full Text] [Related]
5. Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment.
Zhang N; Zhang H; Wang Z; Dai Z; Zhang X; Cheng Q; Liu Z
Front Immunol; 2021; 12():691811. PubMed ID: 34489938
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance and immunogenomic landscape analysis of glycolysis-associated prognostic model to guide clinical therapy in hepatocellular carcinoma.
Chen Q; Bao L; Huang Y; Lv L; Zhang G; Chen Y
J Gastrointest Oncol; 2022 Jun; 13(3):1351-1366. PubMed ID: 35837198
[TBL] [Abstract][Full Text] [Related]
7. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
8. Use of Novel m6A Regulator-mediated Methylation Modification Patterns in Distinct Tumor Microenvironment Profiles to Identify and Predict Glioma Prognosis and Progression, T-cell Dysfunction, and Clinical Response to ICI Immunotherapy.
Zhao B; Xiang Z; Wu B; Zhang X; Feng N; Wei Y; Zhang W
Curr Pharm Des; 2023; 29(1):60-78. PubMed ID: 36503445
[TBL] [Abstract][Full Text] [Related]
9. Human Mitochondrial Ribosomal RNA Modification-Based Classification Contributes to Discriminate the Prognosis and Immunotherapy Response of Glioma Patients.
Wang P; Li J; Wu M; Ye M; Huang K; Zhu X
Front Immunol; 2021; 12():722479. PubMed ID: 34566979
[TBL] [Abstract][Full Text] [Related]
10. Glycolysis induces Th2 cell infiltration and significantly affects prognosis and immunotherapy response to lung adenocarcinoma.
Zeng L; Liang L; Fang X; Xiang S; Dai C; Zheng T; Li T; Feng Z
Funct Integr Genomics; 2023 Jul; 23(3):221. PubMed ID: 37400733
[TBL] [Abstract][Full Text] [Related]
11. A combined signature of glycolysis and immune landscape predicts prognosis and therapeutic response in prostate cancer.
Guo T; Wang J; Yan S; Meng X; Zhang X; Xu S; Ren S; Huang Y
Front Endocrinol (Lausanne); 2022; 13():1037099. PubMed ID: 36339430
[TBL] [Abstract][Full Text] [Related]
12. Characterization of aging tumor microenvironment with drawing implications in predicting the prognosis and immunotherapy response in low-grade gliomas.
Zhou Z; Wei J; Jiang W
Sci Rep; 2022 Mar; 12(1):5457. PubMed ID: 35361903
[TBL] [Abstract][Full Text] [Related]
13. Lipid metabolism-related gene signature predicts prognosis and depicts tumor microenvironment immune landscape in gliomas.
Li J; Zhang S; Chen S; Yuan Y; Zuo M; Li T; Wang Z; Liu Y
Front Immunol; 2023; 14():1021678. PubMed ID: 36860853
[TBL] [Abstract][Full Text] [Related]
14. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
15. Classification related to immunogenic cell death predicts prognosis, immune microenvironment characteristics, and response to immunotherapy in lower-grade gliomas.
Kuang Y; Jiang B; Zhu H; Zhou Y; Huang H; Li C; Zhang W; Li X; Cao Y
Front Immunol; 2023; 14():1102094. PubMed ID: 37153540
[TBL] [Abstract][Full Text] [Related]
16. Development of a tumor microenvironment-related prognostic signature in glioma to predict immune landscape and potential therapeutic drugs.
Zhang Y; Wu C; Li Q; Fang S; Hou M; Zhang S; Dong X
J Biochem Mol Toxicol; 2023 Oct; 37(10):e23448. PubMed ID: 37365744
[TBL] [Abstract][Full Text] [Related]
17. Tumor Microenvironment Characterization for Assessment of Recurrence and Survival Outcome in Gastric Cancer to Predict Chemotherapy and Immunotherapy Response.
Chen Y; Sun Z; Wan L; Chen H; Xi T; Jiang Y
Front Immunol; 2022; 13():890922. PubMed ID: 35572498
[TBL] [Abstract][Full Text] [Related]
18. Construction and validation of immune-related LncRNAs classifier to predict prognosis and immunotherapy response in laryngeal squamous cell carcinoma.
Wang X; Pan Y; Ou Y; Duan T; Zou Y; Zhou X
World J Surg Oncol; 2022 May; 20(1):164. PubMed ID: 35606755
[TBL] [Abstract][Full Text] [Related]
19. Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas.
Ye L; Tong S; Wang Y; Wang Y; Ma W
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9857-9876. PubMed ID: 37248320
[TBL] [Abstract][Full Text] [Related]
20. Machine learning-based glycolysis-associated molecular classification reveals differences in prognosis, TME, and immunotherapy for colorectal cancer patients.
Wang Z; Shao Y; Zhang H; Lu Y; Chen Y; Shen H; Huang C; Wu J; Fu Z
Front Immunol; 2023; 14():1181985. PubMed ID: 37228620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
